Woodline Partners LP Increases Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Woodline Partners LP increased its stake in Regeneron Pharmaceuticals by 2.8% during Q1, bringing its total position to approximately $67.37 million with 106,217 shares.
• Regeneron Pharmaceuticals reported $12.89 earnings per share for the last quarter, significantly exceeding analysts' expectations of $8.43, with a revenue of $3.68 billion.
• The company also announced a quarterly dividend of $0.88 per share, reflecting an annualized dividend yield of 0.6% and a payout ratio of 8.87%.

Woodline Partners LP raised its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 2.8% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 106,217 shares of the biopharmaceutical company's stock after acquiring an additional 2,938 shares during the period. Woodline Partners LP owned approximately 0.10% of Regeneron Pharmaceuticals worth $67,366,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Pinney & Scofield Inc. acquired a new stake in Regeneron Pharmaceuticals during the 4th quarter valued at approximately $25,000. E Fund Management Hong Kong Co. Ltd. lifted its stake in shares of Regeneron Pharmaceuticals by 344.4% in the 1st quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock valued at $25,000 after purchasing an additional 31 shares during the period. Activest Wealth Management lifted its stake in shares of Regeneron Pharmaceuticals by 110.5% in the 1st quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company's stock valued at $25,000 after purchasing an additional 21 shares during the period. Costello Asset Management INC acquired a new position in shares of Regeneron Pharmaceuticals in the 1st quarter valued at $27,000. Finally, Saudi Central Bank acquired a new position in shares of Regeneron Pharmaceuticals in the 1st quarter valued at $27,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Price Performance

Shares of Regeneron Pharmaceuticals stock traded down $8.20 during trading hours on Friday, reaching $560.00. 602,540 shares of the company's stock were exchanged, compared to its average volume of 942,825. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $1,170.58. The company has a market capitalization of $59.35 billion, a P/E ratio of 14.11, a price-to-earnings-growth ratio of 1.90 and a beta of 0.35. The business has a fifty day moving average of $564.61 and a two-hundred day moving average of $579.66. The company has a quick ratio of 3.72, a current ratio of 4.60 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $8.43 by $4.46. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The business had revenue of $3.68 billion during the quarter, compared to analyst estimates of $3.30 billion. During the same quarter in the prior year, the firm earned $11.56 earnings per share. The company's revenue for the quarter was up 3.6% compared to the same quarter last year. As a group, research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, September 3rd. Stockholders of record on Monday, August 18th were issued a dividend of $0.88 per share. The ex-dividend date of this dividend was Monday, August 18th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.6%. Regeneron Pharmaceuticals's dividend payout ratio is presently 8.87%.

Analyst Upgrades and Downgrades

REGN has been the subject of several analyst reports. Morgan Stanley reiterated an "overweight" rating and issued a $761.00 target price (up from $754.00) on shares of Regeneron Pharmaceuticals in a research note on Friday, August 1st. BMO Capital Markets boosted their target price on shares of Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the company an "outperform" rating in a research note on Monday, August 4th. Royal Bank Of Canada boosted their target price on shares of Regeneron Pharmaceuticals from $688.00 to $695.00 and gave the company a "sector perform" rating in a research note on Monday, August 4th. Raymond James Financial upgraded shares of Regeneron Pharmaceuticals to a "moderate buy" rating in a research note on Tuesday, September 2nd. Finally, JPMorgan Chase & Co. reduced their price objective on shares of Regeneron Pharmaceuticals from $950.00 to $800.00 and set an "overweight" rating for the company in a research report on Monday, June 9th. Three analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $817.67.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.